AbCellera Biologics Inc. · NASDAQ:ABCL

AbCellera Biologics — Investor Presentation (August 2025)

32 slides from AbCellera Biologics's investor presentation, August 2025

1. Slide 1: AbCellera Corporate Overview

   AbCellera Corporate Overview COPYRIGHT © ABCELLERA August 2025

2. Slide 2: Disclaimer

   DISCLAIMER This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act actual results, levels of activity, perfor

3. Slide 3: AbCellera is a clinical-stage biotech with integrated capabilities

   AbCellera is a clinical-stage biotech with integrated capabilities TECHNOLOGY for antibody drug Corporate Overview TEAM creation. PLATFORM Our platform combines computation, engineering, molecular design, and biology to support the discovery, development, and clinical manufacturing of differentiated

4. Slide 4: Use our competitive advantage in antibody drug creation

   STRATEGY Use our competitive Build a competitive advantage advantage in antibody Investments in technological capability can improve the productivity of drug drug creation to build a Corporate Overview development. pipeline of differentiated So you can solve hard problems assets. Long-term value cre

5. Slide 5: Our engine was built through 10 years of drug discovery partnerships

   100+ 18 Our engine was built partnered-initiated molecules have through 10 years of therapeutic programs* reached the clinic* drug discovery AbbVie partnerships. Corporate Overview Since 2014, we have partnered with some of the industry’s most innovative pharma and biotech companies. Partnerships we

6. Slide 6: Internal Pipeline & Programs

   INTERNAL PIPELINE & PROGRAMS Two programs in the clinic, one program in IND/CTA-enabling studies, and 20+ programs in discovery. MOLECULE TARGET THERAPEUTIC AREA STAGE Discovery IND-Enabling Phase I Phase 2 Phase 3 Corporate Overview ABCL635 NK3R Endocrinology & Women’s Health ABCL575 OX40L Immunolo

7. Slide 7: 2025 Priorities

   2025 PRIORITIES Completed transition into clinical-stage biotech and on track to complete key priorities. Corporate Overview Completion of platform ABCL635 Phase 1 clinical investments by the first Nominated trials initiated (June 2025) an additional half of the year ~$750M development in available c

8. Slide 8: Potential Milestones

   POTENTIAL MILESTONES We expect a number of key milestones in the next 18-24 months. First 2 programs First 2 clinical Intention to submit Corporate Overview start clinical data readouts 1-3 INDs per year trials in Q3 2025 in 2026 Anticipate initiation of Phase 1 Anticipate readout of 20+ internal pr

9. Slide 9: Internal Programs

   9 COPYRIGHT © ABCELLERA Corporate Overview Internal Programs

10. Slide 10: Our Platforms

    OUR PLATFORMS 100% human health n = 27 We are unlocking high-value drug targets. 30% oncology & GPCR & Ion Channel immunology Platform Corporate Overview T-cell engagers n=8 ● Clinically validated, membrane-protein targets with large commercial potential that have proven largely intractable 56% usin

11. Slide 11: ABCL635

    11 COPYRIGHT © ABCELLERA Corporate Overview ABCL635 Internal Programs

12. Slide 12: ABCL635 potential first-in-class antibody for vasomotor symptoms

    INTERNAL PIPELINE & PROGRAMS ABCL635 is a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes). Target Neurokinin 3 receptor (NK3R) Corporate Overview Target Type G protein-coupled receptor (GPCR) Indication Moderate-to-severe vasomotor symptoms (VMS) as

13. Slide 13: ABCL635 NK3R Antagonist

    INTERNAL PIPELINE & PROGRAMS ABCL635 Readout of Phase 1 clinical study NK3R Antagonist anticipated in mid 2026 Science Commercial Opportunity Differentiation Development Path Corporate Overview ● NK3R is a GPCR involved in ● Approximately 40 million ● Potential first-in-class ● Well-established clini

14. Slide 14: ABCL635 Commercial Opportunity

    ABCL635 Commercial Opportunity VMS are highly prevalent, significantly impact health and well-being, and are the most common reason for seeking treatment for menopause. Corporate Overview VMS are a significant burden Millions of women seek treatment VMS are the most common symptoms of Approximately 40

15. Slide 15: Large unmet need for many women suffering from VMS

    ABCL635 Commercial Opportunity Despite effective treatments, there remains a large unmet need for many women suffering from VMS. Corporate Overview Menopause Hormone Therapy (MHT) is an effective treatment ~12% of women are ~8% of women for VMS, and the current contraindicated.1 discontinue MHT with

16. Slide 16: ABCL635 Science: Pre-Menopause

    ABCL635 Science NK3R antagonists are effective non-hormonal options for VMS. Pre-Menopause Corporate Overview COPYRIGHT © ABCELLERA 16

17. Slide 17: ABCL635 Science: Menopause

    ABCL635 Science NK3R antagonists are effective, non-hormonal options for VMS. Menopause Corporate Overview COPYRIGHT © ABCELLERA 17

18. Slide 18: ABCL635 Science: Treatment

    ABCL635 Science NK3R antagonists are effective, non-hormonal options for VMS. Treatment Corporate Overview COPYRIGHT © ABCELLERA 18 Proposed mechanism of action for ABCL635 based on AbCellera nonclinical data and published literature.

19. Slide 19: Approved and soon-to-be-approved NK3R therapies will establish the market

    ABCL635 Differentiation Approved and soon-to-be-approved NK3R therapies will establish the market. Fezolinetant (Veozah®) by Astellas Elinzanetant (LynkuetTM) by Bayer Corporate Overview Small molecule NK3R antagonist Small molecule NK3R and NK1R antagonist Stage Stage Approved by US FDA1 on May 12,

20. Slide 20: ABCL635 Differentiation

    ABCL635 Differentiation ABCL635 is designed to offer an improved treatment option for women with moderate-to-severe VMS due to menopause. An antibody-based therapeutic may provide several benefits over current non-hormonal treatments: Corporate Overview Potential for reduced toxicities & side-effects

21. Slide 21: ABCL575

    COPYRIGHT © ABCELLERA 21 Corporate Overview ABCL575 Internal Programs

22. Slide 22: ABCL575 potential best-in-class antibody for atopic dermatitis

    INTERNAL PIPELINE & PROGRAMS ABCL575 is a potential best-in-class antibody for the treatment atopic dermatitis. Target Corporate Overview OX40 Ligand (OX40L) Indication Atopic Dermatitis (AD) Therapeutic Area Immunology & Inflammation Status Phase 1 COPYRIGHT © ABCELLERA 22

23. Slide 23: ABCL575 OX40L Antagonist

    INTERNAL PIPELINE & PROGRAMS ABCL575 Readout of Phase 1 clinical study OX40L Antagonist anticipated in mid 2026 Science Commercial Opportunity Differentiation Development Path Corporate Overview ● OX40L mechanism of action • Atopic dermatitis is an ● Competitive space with ● Well-established clinica

24. Slide 24: ABCL575 Science: Atopic Dermatitis

    ABCL575 Science ABCL575 targets multiple immune pathways. Atopic Dermatitis Corporate Overview COPYRIGHT © ABCELLERA 24 Furue, M et al. J Clin Med. 2021; 10(12):2578.

25. Slide 25: ABCL575 Science: Treatment

    ABCL575 Science ABCL575 targets multiple immune pathways. Treatment Corporate Overview COPYRIGHT © ABCELLERA Proposed mechanism of action for ABCL575 based on AbCellera nonclinical data and published literature. 25

26. Slide 26: ABCL575 projected dosing interval of once every 6 months

    INTERNAL PIPELINE & PROGRAMS ABCL575 has a projected dosing interval of once every 6 months. The predicted human half-life is 67 days based on mouse pharmacokinetic (PK) data. Modeled exposure based on preclinical PK data* 600 mg 300 mg Corporate Overview *** loading dose maintenance doses 90% predi

27. Slide 27: Royalty Portfolio & Partnered Programs

    Corporate Overview Royalty Portfolio & Partnered Programs COPYRIGHT © ABCELLERA 27

28. Slide 28: Our Partner Portfolio

    OUR PARTNER PORTFOLIO 91% human health: target antigen known n = 87 We built industry- 9% animal leading capabilities health n=9 through partnerships with the top-tier 21% 17% Corporate Overview neurology immunology & inflammation of biotech and pharma partners. 47% 6% 5% oncology infectious ophthal-

29. Slide 29: Partnerships have built a large portfolio of royalties

    Partnerships have built a large portfolio of royalties in future antibody medicines. Cumulative # of Cumulative # of PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC Corporate Overview WITH DOWNSTREAMS Partner-led AbCellera-led The value of this portfolio will mature over time as our partner

30. Slide 30: Partner-initiated programs continue to progress towards the clinic

    Partner-initiated programs continue to progress towards the clinic. Cumulative # of PARTNER-INITIATED PROGRAMS WITH DOWNSTREAM PARTICIPATION* 6 Not Expected to Progress AbCellera Leading or Co-Leading Work 14 In Progress Corporate Overview 4 Clinical Development 5 Preclinical Development 37 Understo

31. Slide 31: Cumulative total of molecules that have reached the clinic

    A cumulative total of 18 molecules have reached the clinic. MOLECULE MOST ADVANCED STAGE THERAPEUTIC AREA(S) PARTNER1 PROGRAM TYPE ABCL635 Clinical trial authorized • endocrinology/women’s health n/a AbCellera-led ABCL575 Clinical trial authorized • immunology & inflammation n/a AbCellera-led bamlani

32. Slide 32: Thank You

    COPYRIGHT © ABCELLERA 32 Corporate Overview THANK YOU

AbCellera Biologics — Investor Presentation (August 2025) on 6ix